Bolt Biotherapeutics, Inc. Common Stock

Day range

$6.20 – $6.87

Open

$6.66

Prev close

$6.27

Volume

379.85K

Market cap

$14.78M

Shares out

1.93M

P/E

—

P/S

2.57

P/B

0.96

P/FCF

—

ROE

-227.4%

ROA

-71.2%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Acquisition completionOct 23, 2026

  On October 23, 2026, Bolt Biotherapeutics, Inc. ... acquired Prana Therapies, Inc. ... in accordance with the terms of the Agreement and Plan of Merger.

• Lease agreementOct 6, 2026

  On October 1, 2026, Bolt Biotherapeutics, Inc. entered into the Second Amendment to Lease with HCP LS Redwood City LLC, relating to the Company's corporate office, laboratory and vivarium facilities located at 800 and 900 Chesapeake Drive, Redwood City, California. The amendment accelerates the lease expiration date to December 31, 2027, or earlier following the closing of a financing or other strategic transaction.

• Annual meeting resultsJun 11, 2026

  On June 10, 2026, Bolt Biotherapeutics, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting") to consider and vote on the three proposals set forth below... The following director nominees were elected to serve as Class II members of the Company's board of directors until the Company's 2029 Annual Meeting of Stockholders.

• Clinical trial resultsOct 2, 2025

  On October 1, 2025, the Company announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2. A strong immune response was observed at the initial dose levels and the Company is in the process of modifying the clinical trial protocol to allow for step-up dosing.

• Stock splitJun 6, 2025

  On June 6, 2025, Bolt Biotherapeutics, Inc., a Delaware corporation (the "Company"), filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company's Certificate of Incorporation (the "Amendment"), to effect a one-for-twenty (1:20) reverse stock split of its outstanding common stock, effective as of June 6, 2025 (the "Reverse Stock Split"). The Amendment provides that at the effective time of the Reverse Stock Split, every 20 shares of the Company's issued and outstanding common stock will be automatically converted into one issued and outstanding share of common stock.

Days to cover

1.0

Short interest

25.74K

Avg volume

42.28K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
  positiveGlobeNewswire Inc.· Apr 25, 2025
• Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
  positiveGlobeNewswire Inc.· Nov 7, 2024
• BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
  negativeGlobeNewswire Inc.· Sep 2, 2024
• BOLT DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLT
  negativeGlobeNewswire Inc.· Sep 1, 2024
• BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
  negativeGlobeNewswire Inc.· Aug 30, 2024